PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
Related Experiment Video
Updated: Jul 27, 2026

12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
D Jones1, J A Woyach2, W Zhao1
1Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
Leukemia
|April 4, 2017
Abstract
No abstract available in PubMed .

